Riot Blockchain Inc. (RIOT) and Aptose Biosciences Inc. (NASDAQ:APTO) Contrasting side by side

Riot Blockchain Inc. (NASDAQ:RIOT) and Aptose Biosciences Inc. (NASDAQ:APTO) compete against each other in the Biotechnology sector. We will contrast them and contrast their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Riot Blockchain Inc. 6.36M 4.86 55.59M -2.81 0.00
Aptose Biosciences Inc. N/A 0.00 25.89M -0.81 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Riot Blockchain Inc. and Aptose Biosciences Inc.

Profitability

Table 2 provides us Riot Blockchain Inc. and Aptose Biosciences Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Riot Blockchain Inc. -874.06% -225.6% -161.4%
Aptose Biosciences Inc. 0.00% 0% 0%

Risk & Volatility

A 3.05 beta means Riot Blockchain Inc.’s volatility is 205.00% more than Standard and Poor’s 500’s volatility. Aptose Biosciences Inc. has a 1.91 beta and it is 91.00% more volatile than Standard and Poor’s 500.

Analyst Recommendations

Riot Blockchain Inc. and Aptose Biosciences Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Riot Blockchain Inc. 0 0 0 0.00
Aptose Biosciences Inc. 0 0 2 3.00

Competitively the average target price of Aptose Biosciences Inc. is $5.5, which is potential 184.97% upside.

Institutional & Insider Ownership

Institutional investors owned 9.8% of Riot Blockchain Inc. shares and 35.1% of Aptose Biosciences Inc. shares. 2.1% are Riot Blockchain Inc.’s share owned by insiders. Insiders Comparatively, owned 20.4% of Aptose Biosciences Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Riot Blockchain Inc. -9.14% -41.72% -62.44% -77.28% -88.42% -94.05%
Aptose Biosciences Inc. -8.61% -12.18% -30.56% -51.73% 12.06% -6.7%

For the past year Riot Blockchain Inc. was more bearish than Aptose Biosciences Inc.

Summary

On 8 of the 10 factors Aptose Biosciences Inc. beats Riot Blockchain Inc.

Bioptix, Inc., through its subsidiary, BiOptix Diagnostics, Inc., develops enhanced surface plasmon resonance technology platform for the detection of molecular interactions. The company also focuses on animal healthcare and owns important intellectual property rights related to veterinary products. In addition, it has granted a license relating to single chain reproductive hormone technology for use in no-human mammals, which is under active development by the licensee bovine rFSH. The company was formerly known as Venaxis, Inc. and changed its name to Bioptix, Inc. in November 2016. Bioptix, Inc. was founded in 2000 and is based in Castle Rock, Colorado.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.